Navigation Links
Landmark trial to evaluate cardioprotective properties of insulin
Date:11/9/2007

BUFFALO, N.Y. -- The ability of insulin to limit heart-tissue damage during a heart attack will be tested in a landmark clinical trial led by Paresh Dandona, M.D., Ph.D., University at Buffalo Distinguished Professor in the departments of Medicine and Pharmacology and Toxicology in the UB School of Medicine and Biomedical Sciences.

Approximately 600 patients at 90 centers in the U.S. and Latin America will be recruited to participate in the two-year INTENSIVE (Intensive Insulin Therapy and Size of Infarct as a Validated Endpoint by Cardiac MRI) trial. Patients in the trial, which is funded by sanofi-aventis, will be treated with two forms of insulin -- insulin glargine and insulin glulisine.

Kaleida Healths Diabetes-Endocrine Center of Western New York, which Dandona directs, will be one of the vanguard centers. The centers research facility, located in UBs New York State Center of Excellence in Bioinformatics and Life Sciences, will serve as the core laboratory.

Richard W. Nesto, M.D., associate professor at Harvard Medical School and chair of cardiovascular medicine at Lahey Clinic Medical Center in Burlington, Mass., will be co-principal investigator, directing the trials cardiovascular aspects.

The trial is based on a pilot study conducted by the diabetes center, which documented that insulin, used to treat and control type 1 and type 2 diabetes, was also cardioprotective.

This pilot study, published in the journal Circulation in 2004, was conducted in 32 patients receiving low-dose insulin. C-reactive protein (CRP) and serum amyloid A (SAA), two critical markers of inflammation, were reduced by 40 percent and 50 percent, respectively, during the 48 hours following a heart attack. Concentrations of three additional inflammatory factors also were significantly lower in those who received insulin, compared to those who did not.

The markers of myocardial damage that we measured were reduced significantly, said Dandona.
'/>"/>

Contact: Lois Baker
ljbaker@buffalo.edu
716-645-5000 x1417
University at Buffalo
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Document Security Systems (Amex: DMC) Invites You to a Landmark Event
2. Less than one-third of women aware of landmark hormone therapy study, Stanford researcher finds
3. Pathway to cell death redefined in landmark study
4. Pathway to cell death redefined in landmark study
5. UCLA to lead local study center in landmark government study of child health
6. Landmark Report: Excess Body Fat Causes Cancer
7. In Landmark Phase III Head-to-Head Study, Prasugrel Statistically Superior to Clopidogrel in Reducing Risk of Heart Attack
8. New Heart Pump Shows Promise in Trial
9. Trial to Test Gene Therapy for Angina in Women
10. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
11. The New England Journal of Medicine Publishes EURIDIS/ADONIS Study Results Showing Dronedarone Maintained Sinus Rhythm in Patients With Atrial Fibrillation or Flutter With no Observed Pro-Arrhythmia

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)... who were treated with cisplatin-based chemotherap...ical side effects and Raynaud-like phenomena, than...ding to a new study published online November 25 i..., Marianne Brydy, M.D., of the Department of Onc...orway, and colleagues conducted a cross-sectional ...
(Date:11/25/2009)...d arthritis, could help newly diagnosed diabetics,...lthDay News) -- A drug commonly used to treat non-...so shows some promise in helping patients newly di...imab (Rituxan), helped patients keep producing som...d destroyed some of their pancreatic beta cells, w...
(Date:11/25/2009)...ONSkincare ®isproudtosupportGNC,seffortstorai...t.Jude ThanksandGiving campaign,$1fromthepurchasep...Balm willbedonatedtoSt.Jude.Additionally,GNCcustom...eckoutatoneoftheir5,000+retaillocationsoratGNC.com...heir2009 ThanksandGiving campaign. ,, "Wearedel...
(Date:11/25/2009)...ccur in children with autism and related condition...es medication combined with a structured training ...researchers and their colleagues. , Published i...merican Academy of Child and Adolescent Psychiatry...te of Mental Health (NIMH) Research Units on Pedia...
(Date:11/25/2009)...e premier resource for life science careers and in...rest™ Hotbed Campaign this morning. , ...25, 2009 -- BioSpace.com, the premier resource for...e third edition of the BioForest™ Hotbed Cam...n is a promotional effort highlighting biotechnolo...
Breaking Medicine News(10 mins):Health News:Type 1 Diabetes May Have a New Foe 2Health News:Type 1 Diabetes May Have a New Foe 3Health News:MISSION Skincare(R) Supports GNC's Efforts To Raise Money for St. Jude Children's Research Hospital(R) 2Health News:Parent training key to improved treatment of behavior problems in children with autism 2Health News:BioSpace Showcases Leading Life-Science Companies in the Northwest 2
... across the Yangtze River will take another two ye...ready changing the local weather, claim scientists... data suggest that the reservoir is cooling the Ya...ty of Maryland in College Park have collaborated w...
...consider home to be the safest place for deliverie...t their children immunised. The Gandhi M...egions of Udaipur district, conducted the study of...ording to the findings, around 94 percent of pregn...
...ons of insect love and desire. The cicada's songs ... how an emitting sex attracts conspecific members...though less conspicuous for us humans, are also si...thought to play a major role in the evolution of m...
..., Volodymyr Tarabara and Tom Voice, are leading an... Tarabara and Voice are leading an internatio...entists from two U.S. research universities, two r...nding of its kind a $2.5 million grant by the Na...
...e of humour or great look is whats really needed t...sing skills . A poll by online dating agenc...umped a lover because they were a miserable kisser... relationship. This was followed by using ...
...s drug dealer has revealed secrets about the singe... The singer and McFadden Kitten split two years ag... daughters Molly, 4, and Lilly Sue, 3. A...out drugs than anything in her life her children,...
Other Medicine News:Health News:China's Three Gorges Dam Changing Local Weather: Scientists 2Health News:Poor Health Practices Plague Rajasthan Tribal Women 2Health News:Another Sexual Attraction is Possible ... 2Health News:Two MSU Professors Spearhead International Water Project 2Health News:Two MSU Professors Spearhead International Water Project 3Health News:Drugs More Important Than Kids for Katona, Says Her Candy Man 2
(Date:11/25/2009)..., NEWYORK,Nov.25/PRNewswire/--Reportlinker.comann...catalogue: ,, PainManagement-GlobalTrends ,...nagement---Global-Trends.html ,, Widespreadava...linics,andtheadventofnewdrugshaveacceleratedthepac...msandreimbursementstructurecontinuetoshapedemandfo...
(Date:11/25/2009)..., MOUNTAINVIEW,Calif.,Nov.25/PRNewswire/-- Chemo...datafromtheCompany,sPROTECT-1(theProspectiveRandom...raficet-EN(TM)(CCX282-B)inpatientswithmoderate-to-...thafavorablesafetyandtolerabilityprofile.Thestudyd...nofdiseaseseverityasdefinedasa70-pointdecreaseinth...
(Date:11/24/2009)..., MADISON,N.J.,Nov.24/PRNewswire-FirstCall/--Ques...dingproviderofdiagnostictesting,informationandserv...ualPiperJaffrayHealthcareConferenceinNewYorkCity.T...09at9:30a.m.EasternTime. ,, Duringtheconference...owthtoapproximate3%,operatingincometoexceed18%ofre...
Breaking Medicine Technology:Reportlinker Adds Pain Management - Global Trends 2Reportlinker Adds Pain Management - Global Trends 3Reportlinker Adds Pain Management - Global Trends 4Reportlinker Adds Pain Management - Global Trends 5ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5Quest Diagnostics To Speak At The 21st Annual Piper Jaffray Healthcare Conference 2Stimulus funding helps K State biochemist study eyes lens in diabetes galactosemia patients 9528 1DynaVox Mayer Johnson Announces the Xpress 54073 1DynaVox Mayer Johnson Announces the Xpress 54073 2DynaVox Mayer Johnson Announces the Xpress 54073 3Hypertronics HyperGrip 28R 29 and D Series Connectors Selected for SynCardias Total Artificial Heart 54069 1Hypertronics HyperGrip 28R 29 and D Series Connectors Selected for SynCardias Total Artificial Heart 54069 2
...N, DC, June 11, 2007 /PRNewswire-FirstCall/ - Paul...ne at Georgetown,University Medical Center, and pr...chem Inc.,s North American Phase III clinical tria...ay an update on,Neurochem,s investigational produc...se (AD). The presentation by Dr. Aisen will take,p...
...tabine achieved both primary and secondary endpoin... observed between,valopicitabine and ribavirin ~, ...all/ -- Idenix,Pharmaceuticals, Inc. today announc...ate triple combination therapy, consisting of,valo...or the,treatment of hepatitis C, pegylated interfe...
Other Medicine Technology:At the 2007 Alzheimer's Association International Conference on the,Prevention of Dementia - Neurochem's U.S. Principal Investigator,Presents Update on Tramiprosate (Alzhemed) 2At the 2007 Alzheimer's Association International Conference on the,Prevention of Dementia - Neurochem's U.S. Principal Investigator,Presents Update on Tramiprosate (Alzhemed) 3At the 2007 Alzheimer's Association International Conference on the,Prevention of Dementia - Neurochem's U.S. Principal Investigator,Presents Update on Tramiprosate (Alzhemed) 4Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 2Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 3Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 4Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 5Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 6
...ities where space is a premium Fabius Tiro combine...gies with an ergonomic and compact design. Adding ...nfinity patient monitoring range allows you to cre...nd investment into the future. The open modular ar...
... using Datex-Ohmedas unique approach to anesthesia...laboration with clinicians. It combines the proven...eda monitoring technology into an affordable syste...world, ,The contemporary, compact design addresse...
...nt Wound Dressing is a sterile, single use bundle ...g applications. The synthetic matrix absorbs exce...ontours, and entraps slough and necrotic debris wi...rands of the matrix are bound together by a matrix...
...sician preference card system as well as a perpetu...management requirements of the surgical services d...h a broad array of inventory management capabiliti...e supply and charge capture workflow. Regardless o...
Medicine Products: